Skip to main content
VRAX
NASDAQ Life Sciences

Shareholders Approve 1-for-10 to 1-for-30 Reverse Stock Split

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.174
Mkt Cap
$3.634M
52W Low
$0.1
52W High
$1.14
52W Position info
74% above low
Off High info
85% below high
Rel. Volume
Market data snapshot near publication time

VRAX sits 74% above its 52-week low of $0.1.

Summary

Virax Biolabs shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, along with amended articles of association to reflect the new share capital structure.


Key Events · Corporate Governance and Compliance · VRAX

  • Reverse Stock Split Approved

    Shareholders approved a share consolidation (reverse stock split) on a basis of one (1) share for every ten (10) to thirty (30) outstanding ordinary shares.

  • Amended Articles of Association Approved

    The form of the fourth amended and restated memorandum and articles of association was approved to reflect the revised authorized share capital, effective with the share consolidation.

  • Extraordinary General Meeting Details

    The Extraordinary General Meeting was initially adjourned due to a lack of quorum (3.6% present) but reconvened on June 12, 2026, where the shareholders present (3.65%) constituted a quorum as per company articles.


Analysis · VRAX · Life Sciences

Shareholders have approved a reverse stock split, a critical move for a company trading at a low share price. This action is typically undertaken to increase the per-share price to meet exchange listing requirements and potentially attract a broader investor base. The wide range of the split (1-for-10 to 1-for-30) gives the board flexibility in determining the final ratio.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VRAX was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.10 to $1.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VRAX - Latest Insights

VRAX
Aug 26, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $2.61 info
Change: -$0.350 (-12%) info
Market Cap: $2.08M info
VRAX
Jul 31, 2026, 7:44 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.94
Real-time Price: $2.61 info
Change: -$0.330 (-11%) info
Market Cap: $2.08M info
VRAX
Jul 24, 2026, 4:20 PM EDT
Filing Type: F-3
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.61 info
Change: -$0.640 (-20%) info
Market Cap: $2.08M info
VRAX
Jul 16, 2026, 7:31 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.11
Real-time Price: $2.61 info
Change: -$1.50 (-36%) info
Market Cap: $2.08M info
VRAX
Jul 10, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.05
Real-time Price: $2.61 info
Change: -$1.44 (-36%) info
Market Cap: $2.08M info